Hara T, Nakamura J, Koh N, Sakakibara F, Takeuchi N, Hotta N
Third Department of Internal Medicine, Nagoya University School of Medicine, Japan.
Diabetes Care. 1996 Jun;19(6):642-7. doi: 10.2337/diacare.19.6.642.
To examine the usefulness of alpha-glucosidase inhibitors in glycemic control of patients with NIDDM. The involvement of carbohydrate ingestion in manifestation of the effects of alpha-glucosidase inhibitors was also investigated.
A total of 41 patients hospitalized with NIDDM (22 patients receiving sulfonylurea and 19 receiving insulin therapy) were given alpha-glucosidase inhibitors during the period when their blood glucose levels were well controlled. They were followed for 3 weeks as inpatients and for an additional 6 months as outpatients. They were retrospectively divided into two groups according to the percentage of carbohydrates in all sources of calories during outpatient management: the < 50% group and the > 50% group. Between these two groups, we compared circadian variation in blood glucose levels, HbA1c, and urine C-peptide.
Treatment with alpha-glucosidase inhibitors during the hospital stay markedly improved circadian variation in blood glucose levels and HbA1c and decreased urine C-peptide in both groups. While HbA1c returned to its pretreatment level at 6 months after the treatment in the < 50% group, HbA1c had further improved in the > 50% group at 6 months.
alpha-Glucosidase inhibitors are useful for glycemic control in patients with NIDDM and the percentage of carbohydrate in all calorie sources is an important factor for the expression of their effects.
研究α-葡萄糖苷酶抑制剂在非胰岛素依赖型糖尿病（NIDDM）患者血糖控制中的作用。同时探讨碳水化合物摄入对α-葡萄糖苷酶抑制剂疗效表现的影响。
共有41例住院的NIDDM患者（22例接受磺脲类药物治疗，19例接受胰岛素治疗），在其血糖水平得到良好控制期间给予α-葡萄糖苷酶抑制剂。患者住院观察3周，出院后门诊随访6个月。根据门诊管理期间所有热量来源中碳水化合物的百分比，将患者回顾性分为两组：<50%组和>50%组。比较两组患者血糖水平的昼夜变化、糖化血红蛋白（HbA1c）和尿C肽水平。
住院期间使用α-葡萄糖苷酶抑制剂治疗，两组患者的血糖水平昼夜变化和HbA1c均明显改善，尿C肽水平降低。<50%组治疗后6个月时HbA1c恢复至治疗前水平，而>50%组在治疗后6个月时HbA1c进一步改善。
α-葡萄糖苷酶抑制剂对NIDDM患者的血糖控制有效，所有热量来源中碳水化合物的百分比是其疗效表现的重要因素。
